13,30 $
1,68 % gestern
Nasdaq, 30. Oktober, 21:13 Uhr
ISIN
US71722W1071
Symbol
PHAT
Berichte

Phathom Pharmaceuticals Inc Aktie News

Neutral
Seeking Alpha
etwa 14 Stunden alt
Phathom Pharmaceuticals, Inc. ( PHAT ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Eric Sciorilli - Director of Business Development & Investor Relations Steven Basta - CEO, President & Director Sanjeev Narula - Chief Financial & Business Officer Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Kristen Kluska - Cantor ...
Neutral
GlobeNewsWire
etwa 20 Stunden alt
Over 790,000 total VOQUEZNA® prescriptions filled to date Filled VOQUEZNA prescriptions increased 28% from Q2 2025 Net revenues of $49.5 million, up 25% quarter over quarter, and cash operating expenses down 43% quarter over quarter Full-year 2025 revenue guidance updated to $170–$175 million; company expects to achieve operating profitability in 2026 Management to host conference call today, O...
Neutral
GlobeNewsWire
6 Tage alt
FLORHAM PARK, N.J., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that results of additional analyses from its pivotal Phase 3 pHalcon-NERD-301 trial evaluating VOQUEZNA® (vonoprazan) tablets in patients with Non-Erosive Ref...
Neutral
GlobeNewsWire
8 Tage alt
FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology's (ACG) 2025 Annual Scientific Meeting, being held October 24-29 in Phoenix, Arizona.
Neutral
GlobeNewsWire
11 Tage alt
FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update.
Positiv
Seeking Alpha
25 Tage alt
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...
Neutral
GlobeNewsWire
25 Tage alt
Sanjeev Narula brings proven success in scaling commercial-stage biopharma companies with expertise in capital and investor strategies, M&A, and operational excellence Appointment strengthens Phathom's leadership team and ability to execute its growth strategy in GI FLORHAM PARK, N.J., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company fo...
Neutral
GlobeNewsWire
2 Monate alt
FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of its management team are scheduled to participate in the following investor conferences in September:

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen